459 related articles for article (PubMed ID: 29284669)
1.
Zimmerman MW; Liu Y; He S; Durbin AD; Abraham BJ; Easton J; Shao Y; Xu B; Zhu S; Zhang X; Li Z; Weichert-Leahey N; Young RA; Zhang J; Look AT
Cancer Discov; 2018 Mar; 8(3):320-335. PubMed ID: 29284669
[TBL] [Abstract][Full Text] [Related]
2. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
4. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.
Zeid R; Lawlor MA; Poon E; Reyes JM; Fulciniti M; Lopez MA; Scott TG; Nabet B; Erb MA; Winter GE; Jacobson Z; Polaski DR; Karlin KL; Hirsch RA; Munshi NP; Westbrook TF; Chesler L; Lin CY; Bradner JE
Nat Genet; 2018 Apr; 50(4):515-523. PubMed ID: 29379199
[TBL] [Abstract][Full Text] [Related]
5. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
[TBL] [Abstract][Full Text] [Related]
6. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
[TBL] [Abstract][Full Text] [Related]
7. Rare MYC-amplified Neuroblastoma With Large Cell Histology.
Matsuno R; Gifford AJ; Fang J; Warren M; Lukeis RE; Trahair T; Sugimoto T; Marachelian A; Asgharzadeh S; Maris JM; Ikegaki N; Shimada H
Pediatr Dev Pathol; 2018; 21(5):461-466. PubMed ID: 29426276
[TBL] [Abstract][Full Text] [Related]
8. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
[TBL] [Abstract][Full Text] [Related]
9. Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma.
Helmsauer K; Valieva ME; Ali S; Chamorro González R; Schöpflin R; Röefzaad C; Bei Y; Dorado Garcia H; Rodriguez-Fos E; Puiggròs M; Kasack K; Haase K; Keskeny C; Chen CY; Kuschel LP; Euskirchen P; Heinrich V; Robson MI; Rosswog C; Toedling J; Szymansky A; Hertwig F; Fischer M; Torrents D; Eggert A; Schulte JH; Mundlos S; Henssen AG; Koche RP
Nat Commun; 2020 Nov; 11(1):5823. PubMed ID: 33199677
[TBL] [Abstract][Full Text] [Related]
10. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
[No Abstract] [Full Text] [Related]
11. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
12. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
[TBL] [Abstract][Full Text] [Related]
13. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
14. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
15. Human neuroblastoma cell lines that express N-myc without gene amplification.
Wada RK; Seeger RC; Brodeur GM; Einhorn PA; Rayner SA; Tomayko MM; Reynolds CP
Cancer; 1993 Dec; 72(11):3346-54. PubMed ID: 8242562
[TBL] [Abstract][Full Text] [Related]
16.
Cancer Discov; 2018 Apr; 8(4):OF11. PubMed ID: 29439151
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
[TBL] [Abstract][Full Text] [Related]
18. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
19. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
20. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]